Market Research Logo

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H2 2018

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H2 2018

Summary

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) pipeline Target constitutes close to 25 mole


Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Overview
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Astellas Pharma Inc
BerGenBio ASA
Betta Pharmaceuticals Co Ltd
Celldex Therapeutics Inc
Daiichi Sankyo Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
F1 Oncology Inc
Genosco Inc
Incyte Corp
Les Laboratoires Servier SAS
Mirati Therapeutics Inc
Ono Pharmaceutical Co Ltd
Oribase Pharma
Qurient Co Ltd
Rigel Pharmaceuticals Inc
SignalChem Lifesciences Corp
Takeda Pharmaceutical Co Ltd
Tolero Pharmaceuticals Inc
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Drug Profiles
Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bemcentinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGB-149 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-9016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-30138 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-053 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-1205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Inhibit Axl Tyrosine kinase for Non-Small Cell Lung Cancer and Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gilteritinib fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOPE-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-81776 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORY-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-916562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXDX-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-49076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sitravatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKIG-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLC-391 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AXL for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MERTK and AXL for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0903 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Discontinued Products
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Nov 02, 2018: BerGenBio to present late-breaking abstract on Phase II trial of bemcentinib in combination with KEYTRUDA in advanced NSCLC at SITC
Oct 22, 2018: BerGenBio announces interim biomarker and phase II clinical data with selective AXL inhibitor Bemcentinib presented at ESMO
Oct 22, 2018: Exelixis announces results from the dose-escalation stage of the phase 1b COSMIC-021 study of Cabozantinib in combination with Atezolizumab in previously untreated advanced renal cell carcinoma
Oct 21, 2018: Mirati Therapeutics announces updated data from ongoing clinical trial of single agent Sitravatinib at the 2018 ESMO Congress
Oct 20, 2018: Exelixis announces results from two analyses evaluating effect of PD-L1expression or prior treatment with checkpoint inhibitors on efficacy of Cabozantinib in patients with advanced renal cell carcinoma
Oct 19, 2018: Daiichi Sankyo initiates phase 1 study of AXL inhibitor DS-1205 in patients with EGFR-mutated metastatic non-small cell lung cancer
Oct 15, 2018: Mirati therapeutics to provide updated Sitravatinib clinical data at the European Society for Medical Oncology (ESMO) 2018 congress and conduct investor call
Oct 12, 2018: Ipsen to present data on Cabometyx at ESMO 2018
Oct 09, 2018: BerGenBio to present interim phase II clinical, preclinical and biomarker data with selective AXL inhibitor Bemcentinib at ESMO
Oct 08, 2018: Cabozantinib to be featured in 13 presentations at ESMO 2018 Congress
Oct 08, 2018: BerGenBio doses first patient in second part of BGBC008 trial
Oct 08, 2018: Exelixis initiates phase 3 pivotal trial (COSMIC-311) of Cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy
Sep 28, 2018: Invivoscribe receives approval in Japan for its LeukoStrat CDx FLT3 Mutation Assay for the assessment of acute myeloid leukemia (AML) patients treated with Xospata (gilteritinib fumarate)
Sep 25, 2018: BerGenBio: Updated phII clinical data with selective AXL inhibitor bemcentinib strengthens its potential to improve NSCLC patient outcomes
Sep 21, 2018: Astellas announces approval in Japan for XOSPATA 40 mg tablets for the treatment of FLT3mut+ Relapsed or Refractory AML
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..3), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1)
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Products under Development by Companies, H2 2018 (Contd..5), H2 2018
Products under Development by Companies, H2 2018 (Contd..6), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Astellas Pharma Inc, H2 2018
Pipeline by BerGenBio ASA, H2 2018
Pipeline by Betta Pharmaceuticals Co Ltd, H2 2018
Pipeline by Celldex Therapeutics Inc, H2 2018
Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pipeline by Exelixis Inc, H2 2018
Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Pipeline by F1 Oncology Inc, H2 2018
Pipeline by Genosco Inc, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Les Laboratoires Servier SAS, H2 2018
Pipeline by Mirati Therapeutics Inc, H2 2018
Pipeline by Ono Pharmaceutical Co Ltd, H2 2018
Pipeline by Oribase Pharma, H2 2018
Pipeline by Qurient Co Ltd, H2 2018
Pipeline by Rigel Pharmaceuticals Inc, H2 2018
Pipeline by SignalChem Lifesciences Corp, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Tolero Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report